Under the Paperwork Reduction Act of 1995, no persons are requ to a collection of information unless it contains a valid CMB control number. F

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor Sada		hiko YASUKAWA
Art Unit		
Examiner Name		
Attorney Docket Numb	er	70404 95/ha

				U.S.I	PATENTS			Remove	l	
Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	Date	Name of Patentee or Applicant of cited Document					
1										
h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		_
		U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		_
Cite No	Publication Number	Kind Code <sup>1</sup>		tion	Name of Patentee or Applicant Rele		Releva	nt Passa		
1	20020024624	A1	2006-0	2-28	TAKENAKA					
n to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d button	Add		_
			FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Cite No	Foreign Document Number <sup>3</sup>			or	vhere Rel	evant or Relevant	75			
1										Е
n to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		_
		NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		_
	No 1 Cite No 1 Cite No 1 Cite No 1	No Patent Number  1  1  10 add additional U.S. Paten  Cite No Publication Number  1 20020024624  10 add additional U.S. Publication Number  Cite Foreign Document  No Number <sup>3</sup>	No Patent Number Code1  1	No Patent Number Code   Issue II  1	1	No Patent Number Code*   sesue Date of cited Docu-  1	No Patent Number Code!	Citie   Patient Number   Code   Issue Date   Name of Patienties or Applicant   Relever	Cide   Patent Number   Code*   Issue Date   Name of Patentee or Applicant   Relevant Passa   Relevant Passa	No Patent Number   Codes   Issue Date   of cited Document   Pages of Yeave   Pages of Yeave    1   1   1   1   1   1   1   1   1

	Application Number		
NEODIA TION DIOOL COURT	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Sadahiko YASUKAWA	
( Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	er	70404.95/ha

	1			
If you wis	h to a	d additional non-patent literature document citation information please click the Add button	Add	

EXAMINER SIGNATURE

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Code of USPTO Patent Documents at invenUSPTO.GOV or MPEP 90194. 2 Enter office that issued the document, by the hor-lefter office (WIPO Standard ST3.). <sup>1</sup> The Jungarees patent document, the ordination of the year of the region of the Emperor many precede the sent annumber of the patent document. <sup>1</sup> Annu of document by the appropriate symbols as andicated on the document under WIPO Standard ST.16 if possole, <sup>2</sup> Applicant is to place a check mark here if Emploits anguage the sent annumber of the patent document under WIPO Standard ST.16 if possole, <sup>2</sup> Applicant is to place a check mark here if Emploits insignate entraination is attached.

# Application Number Filing Date Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Sadahko YASUKAWA Art Unit Examiner Name Attorney Docket Number 70404.95tha

## CERTIFICATION STATEMENT

Please see 37	CFR 1 97	and 1.98 to	make the app	ropriate selection(s):

information disclosure statement. See 37 CFR 1.97(e)(1).

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to fix the office in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Christopher A. Bennett #46,710/	Date (YYYY-MM-DD)	2006-08-21							
Name/Print	Christopher A. Bennett	Registration Number	46710							

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.